City of Hope provides cancer support services to Amazon employees

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

City of Hope announced a partnership to provide a range of enhanced cancer support services to Amazon employees in the U.S.—including a dedicated phone line staffed by oncology nurses, specialized support for complex cancers and diagnosis and treatment plan review.

Amazon employs more than 275,000 people across the U.S.

The services include:

  • Cancer Support Line
    Whether an employee has a question about the side effects of treatment or needs emotional support, a dedicated team of cancer care nurses is available to answer questions and provide information. Employees can call about their own diagnosis or if a family member is diagnosed with cancer.

  • Expert Review
    Employees can benefit from this subspecialized expertise in their own communities by requesting that a City of Hope physician review their diagnosis and treatment plan and provide a written recommendation to the patient’s treating physician regarding the clinical appropriateness of the proposed therapeutic approach. If appropriate, City of Hope physicians will recommend improvements to the proposed treatment plan, including recommendations for–and interpretation of–genetic/genomic testing, identification of potential clinical trials and therapeutic options. An employee may also choose to go to City of Hope for an in-person evaluation with its premier physicians.

  • City of Hope Accountable Precision Oncology Program
    City of Hope specialists work with Amazon’s health plans to support the care of patients with the most complex cancers. City of Hope cancer experts directly engage local primary oncologists to provide a recommendation for appropriate genetic testing and accurate interpretation of test results and advice for optimal treatment, including the appropriate use of the most leading edge, targeted therapies.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login